Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Long-Term Investments came in at $22.2 million in Q2 2026, down 67.68% YoY from $68.6 million in Q2 2025, and little changed on a QoQ basis from $22.2 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Long-Term Investments data on file, last reported at $22.2 million in Q2 2026.
- Quarterly Long-Term Investments fell 67.68% year-over-year to $22.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $22.2 million (down 67.68% YoY) and the FY2025 annual result came in at $22.2 million, down 67.68% from the prior year.
- Long-Term Investments was little changed at $22.2 million in Q2 2026, from $22.2 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $68.6 million in Q4 2024 to a low of $22.2 million in Q4 2025.
- A 5-year average of $48.8 million and a median of $49.4 million in 2022 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2024 — Long-Term Investments soared 38.88% — and 2025, when it slumped 67.68%.
- Tracing ALNY's Long-Term Investments over 5 years: stood at $49.4 million in 2022, then grew by 0.0% to $49.4 million in 2023, then soared by 38.88% to $68.6 million in 2024, then tumbled by 67.68% to $22.2 million in 2025, then increased by 0.0% to $22.2 million in 2026.
- The last three Long-Term Investments figures came in at $22.2 million (Q2 2026), $22.2 million (Q1 2026), and $22.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.17 Mn |
| Mar 31, 2026 | 22.17 Mn |
| Dec 31, 2025 | 22.17 Mn |
| Sep 30, 2025 | 51.31 Mn |
| Jun 30, 2025 | 68.59 Mn |
| Mar 31, 2025 | 68.59 Mn |
| Dec 31, 2024 | 68.59 Mn |
| Sep 30, 2024 | 68.59 Mn |
| Jun 30, 2024 | 49.39 Mn |
| Mar 31, 2024 | 49.39 Mn |
| Dec 31, 2023 | 49.39 Mn |
| Sep 30, 2023 | 49.39 Mn |
| Jun 30, 2023 | 49.39 Mn |
| Mar 31, 2023 | 49.39 Mn |
| Dec 31, 2022 | 49.39 Mn |
| Sep 30, 2022 | 49.39 Mn |
| Jun 30, 2022 | 49.39 Mn |
| Mar 31, 2022 | 40.89 Mn |
| Dec 31, 2021 | 40.89 Mn |
| Sep 30, 2021 | 40.89 Mn |